Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Item
http://www.wikidata.org/entity/Q44845388
Molecular biology of lung cancerNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerIrreversible EGFR-TKIs: dreaming perfectionTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerThe predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaEGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.Rational design of non-resistant targeted cancer therapiesRoutine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.The quest to overcome resistance to EGFR-targeted therapies in cancer.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyLung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response predictionDNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsEGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaA novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib.Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaSingle-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off ProbesCommon and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.Advances on EGFR mutation for lung cancer.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatmentComparison of uncommon EGFR exon 21 L858R compound mutations with single mutation.EGFR: The Paradigm of an Oncogene-Driven Lung CancerDetection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patientsCirculating Cell-Free Tumour DNA in the Management of Cancer.Screening for germline EGFR T790M mutations through lung cancer genotyping.
P2860
Q24606677-5F71F242-7334-4D17-8329-F5533BBE2F05Q26744284-AE55CD3C-D77D-4E7D-8DB6-641D7A528AD1Q26744339-68072286-0FB9-49D6-B87B-A363E8E96EFAQ26797297-2BDF904E-F4EF-4619-8E9C-1A8CB1DF43ABQ26797471-452BA9B7-3654-4642-A9E5-332A784AD3F5Q26852507-07D76BA2-25BB-4006-B597-84D1B0F206F5Q26866186-38DCFB7D-2FD4-4050-BA92-10FB387DC082Q27014117-8EC205E6-B9D9-4C56-8C70-5752BC874752Q27680966-A84CEDFD-C6AA-4946-BD68-5B5F09FECC45Q27852950-08EAE4B0-E504-40D3-B2A9-2EE3FF261E52Q28069900-6641DCF4-3843-4F92-8A4A-0777B5ACF48AQ30397503-B808B71C-055E-4F0A-8470-A59543F26EEFQ33594692-F01A58EB-2F58-4D3C-A17B-10E1F272C0EAQ33599057-14C20020-7AD0-4B4B-84C0-A05182157313Q33653097-FEF1609C-8476-4A02-83E3-3D8A437E2C7CQ33700689-CE10D106-6515-454B-ADB8-45E151FE8538Q33706859-0FE0C7E2-D4A4-41A9-8778-52ED66B790C1Q33725976-DBBAD344-441B-4872-BC10-F8B7FE068007Q33757134-DBBDED5F-3819-4F7D-8DAE-88F06FDE0B56Q33897441-9089EC21-D4DE-4B26-A870-9D46432A4E1BQ33999412-A5FF4B4B-9F34-41C2-830E-D8A10F4015B9Q34002791-076938F9-5887-4B58-AE2B-099D60F41E53Q34032012-EED22ADA-0DD3-470C-93F6-12F8F42D1717Q34041701-BFF1B955-DE6A-4FF2-88C1-E69E78868560Q34055400-AF233B56-8C54-4627-9453-481D71CE177CQ34108365-65B8437E-15C5-460C-9BAD-58BA6025B1FDQ34131441-520CDC70-C89C-4456-80D1-501A8438BA34Q34134464-541EE0AF-9576-4C92-B0CD-C78AB5269C2BQ34172448-1933AFB9-997F-4C5D-8FF3-BAA11E2D20DAQ34523257-1E653A7D-A9C3-46C8-9E7B-DD5DB8DDD04CQ34906960-EF6C07A2-49FA-4CD7-BB91-C8B6D5896311Q35082587-5361B9D6-D690-48EF-A24B-6D9A2567CC0DQ35200375-DE4092AE-5392-4795-9184-74677820156DQ35227986-91A32C4F-B193-408F-A9FD-1AB7FB6BA433Q35541933-768D6FD1-4394-4956-A74F-D929884BF875Q35619241-49B96269-642A-4148-94E6-93AE8BA0E6ACQ35787132-F0295BBC-D4C5-45FB-AC5C-C975F2485D7AQ35812818-5456C4D2-5B82-49E1-A699-ACFDFB208AE5Q35814162-A17A06DC-F0E9-4D6B-83A0-4D136F890DC8Q35967349-03DC4188-ABB6-47B2-9803-C9A38AC4F1AC
P2860

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Item
http://www.wikidata.org/entity/Q44845388
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@en
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@nl
type
label
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@en
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@nl
prefLabel
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@en
Effectiveness of tyrosine kina ...... in non-small cell lung cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Effectiveness of tyrosine kina ...... in non-small cell lung cancer
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-10-3408
P407
P433
P478
P50
P577
P698